Apr. 2 at 12:43 PM
$HRMY
Summary
--Commercial Success: Driven by WAKIX (pitolisant), which delivered
$868.5 million in net revenue for FY 2025 (22% YoY growth).
--2026 Guidance: Revenue projected at
$1.0 billion to
$1.04 billion, elevating WAKIX to blockbuster status.
--Durability: Settled with 6 of 7 ANDA filers; generic entry is barred until March 2030 (pending pediatric exclusivity).
--Portfolio Expansion: Actively transitioning to next-gen pitolisant formulations and diversifying into rare epilepsy (Epygenix acquisition).
Pipeline and Mechanism of Action (MOA)
--WAKIX (pitolisant): A selective histamine 3 (H3) receptor antagonist/inverse agonist. It increases histamine release in the brain to stabilize sleep-wake states. Unique as the only non-scheduled (non-DEA) narcolepsy treatment.
--Pitolisant GR (Gastro-resistant): A new formulation designed to improve GI tolerability and allow for therapeutic dosing without initial titration.
--Pitolisant HD (High Dose): Targeting superior efficacy in narcolepsy and Idiopathic Hypersomnia (IH) by focusing on fatigue and sleep inertia.
--BP1.15205: A potential best-in-class Orexin-2 receptor agonist. It targets the loss of orexin signaling, the primary cause of Narcolepsy Type 1.
--EPX-100 (clemizole hydrochloride): A 5HT2 serotonin agonist for refractory childhood epilepsies (Dravet and Lennox-Gastaut syndromes).
Catalyst Readout Timeline
--2H 2026: Phase 3 TEMPO topline data for Pitolisant in Prader-Willi Syndrome (PWS).
--Q2 2026: Planned NDA submission for Pitolisant GR.
--Mid-2026: Phase 1 clinical PK data for Orexin-2 agonist (BP1.15205).
--Q1 2027: Expected PDUFA date for Pitolisant GR.
--1H 2027: Phase 3 topline data for EPX-100 in Dravet and Lennox-Gastaut syndromes.
--2027: Phase 3 topline data for Pitolisant HD in Narcolepsy and IH.
Competition and Competitive Positioning
--Current Direct Competition
----Jazz Pharmaceuticals: Xywav/Xyrem (oxybates) are standard for cataplexy but carry heavy REMS restrictions and safety warnings.
----Avadel Pharmaceuticals: Lumryz (once-nightly oxybate) competes on dosing convenience, though still subject to REMS.
--Emerging Orexin-2 (OX2R) Agonists
----Takeda – Oveporexton (TAK-861): Most immediate threat; FDA Priority Review with Q3 2026 PDUFA. Potential first-line "disease-modifying" therapy for NT1.
----Alkermes – Alixorexton (ALKS 2680): Granted Breakthrough Therapy designation; entering Phase 3 in early 2026.
----Eli Lilly / Centessa – ORX750: Phase 2a high-potency program targeting NT1, NT2, and IH with major pharma backing.
--Harmony’s Strategy & Differentiators
----The Hedge: BP1.15205 is Harmony’s in-house OX2R agonist (Phase 1); vital for long-term relevance in the post-orexin market. >600 fold selectivity over OX1R and potential higher potency.
----Non-Scheduled Advantage: WAKIX remains the only non-scheduled option, avoiding the administrative friction and abuse-potential labels of all current and likely future competitors.
--Market Penetration: Currently serving ~8,500 patients out of ~80,000 diagnosed U.S. narcolepsy patients.
Financials and Valuation
--Fully Diluted Share Count: ~61.5 million shares (Includes ~57.7M basic plus ~3.8M dilutive units).
--Fully Diluted Market Cap (at
$28/share): ~
$1.72 Billion.
--Cash Position:
$882.5 million in cash and investments as of Dec 31, 2025.
--Buybacks:
$150 million remaining in authorized share repurchase program.
Team
--Jeffrey Dayno, M.D. (CEO): Neurologist; former CMO at Harmony. Previously led clinical development and medical affairs for CNS brands at Cephalon and ViroPharma.
--Peter Anastasiou (COO): Former CEO of Capsida; spent 11 years at Lundbeck as President of North America, overseeing multiple major neurological drug launches.
--Sandip Kapadia (CFO): Former CFO of Intercept; 19-year tenure at Novartis, including leadership roles as CFO of Novartis India and European Controller.
--Kumar Budur, M.D. (CMO): Former neuroscience lead at AbbVie and medical faculty at Cleveland Clinic; extensive experience in clinical development for successful CNS assets.
Bull Thesis
--Commercial Proof: WAKIX has a high-growth trajectory and established payer coverage.
--Lifecycle Extension: Next-gen formulations (GR/HD) could extend patent protection into the 2040s, bypassing the 2030 cliff.
--Orexin Upside: BP1.15205 provides a hedge and entry into the next-generation narcolepsy market.
--Valuation Read-Through: Lilly’s
$6.3 billion acquisition of Centessa (Phase 2a orexin) highlights the massive disconnect in Harmony’s market cap (~
$1.7B) relative to its commercial revenue and Phase 1 orexin agonist (BP1.15205).
--Cash Rich: Strong balance sheet supports aggressive M&A and continued share buybacks.
Bear Thesis
--Generic Entry: Potential for revenue erosion in 2030 if the patient switch to next-gen formulations is unsuccessful.
--R&D Risks: Label expansion is difficult, as evidenced by the previous Pitolisant IH refusal-to-file in early 2025.
--Crowded Orexin Field: Competitors (Takeda/Jazz) are further ahead in Orexin development.
--Bioprojet Reliance: Core IP and much of the pipeline are licensed from a single partner.
fyi @Night_Owl_Biotech
